法国DAILY-LUMA队列:lumasiran应答的预测因素
该研究基于法国DAILY-LUMA队列,纳入76例原发性高草酸尿症1型患者,评估基因型与lumasiran应答的关联。治疗3个月时73%患者达到主要终点,基因型与应答无显著关联,诊断年龄和lumasiran起始年龄是仅有显著决定因素,儿童应答更佳。
要点
- lumasiran治疗3个月时73%患者达到复合应答终点。
- 基因型与lumasiran应答无显著关联,儿童应答优于成人。
- 吡哆醇敏感型患者建议继续或启动吡哆醇治疗。
核心结论
- lumasiran应答在儿童中更佳,且不依赖于 underlying 基因型。
- 吡哆醇敏感型患者建议在lumasiran起始后继续或启动吡哆醇。
- lumasiran起始后应系统进行密切随访和再评估。
研究设计与样本
- 正在进行的法国DAILY-LUMA队列,评估lumasiran真实世界疗效与安全性。
- 共纳入76例患者(54例儿童),lumasiran起始中位年龄13岁(IQR 4-33),24例接受透析。
- 于治疗起始及第3、6、12个月收集数据。
主要发现
- 治疗3个月时73%患者达到主要终点(基于可用数据计算)。
- 基因型与lumasiran应答无显著关联,但吡哆醇敏感型呈应答较弱的趋势。
- 与主要终点显著相关的决定因素仅为诊断年龄和lumasiran起始年龄,儿童应答最佳。
关键数值与推荐
- 主要终点为3个月时达到复合标准:eGFR≥30 mL/min/1.73 m2者尿草酸/肌酐比值(UOx/Creat)正常化和/或较基线下降>30%,或eGFR<30 mL/min/1.73 m2者血草酸(POx)正常化和/或较基线下降>30%。
- 次要终点为6个月和12个月时同一分析。
- 基因型按维生素B6应答分为耐药、敏感、不确定(丙氨酸-乙醛酸氨基转移酶Ile244Thr变异)三组。
临床怎么用
- 儿童PH1患者接受lumasiran可能获得更佳应答。
- 吡哆醇敏感型患者即使起始lumasiran后也应继续或启动吡哆醇。
- lumasiran起始后需密切随访并系统再评估疗效。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Primary Hyperoxaluria type 1 (PH1) is a rare and severe autosomal recessive disorder with genotype/phenotype correlation. The RNA interfering therapy lumasiran has revolutionized its prognosis but with heterogeneous response amongst patients. Here, we assessed a possible association between genotype and lumasiran response. METHODS: In the ongoing French DAILY-LUMA cohort evaluating real-life efficacy and safety of lumasiran, we collected data at treatment initiation and at months three, six and 12 of treatment. The main outcomes were composite criteria, namely normalization and/or reduction over 30% from baseline in the urinary ratio of oxalate and creatinine (UOx/Creat) or in blood oxalate levels (POx) in patients with estimated glomerular filtration rate (eGFR) over or under 30 mL/min/1.73 m2, respectively. The primary endpoint was the proportion of patients reaching this criterion at three months, and secondary endpoints were the same analysis at six and 12 months. Genotype was classified into three groups depending on the vitamin B6 response: resistance, sensitivity, uncertain response (Ile244Thr variant of alanine-glyoxylate aminotransferase). RESULTS: In total, 76 patients (54 children) were included, at a median (inter quartile range) age at lumasiran initiation of 13 (4-33) years with 24 patients on dialysis. After three months of treatment, 73% of patients met the primary endpoint (% calculated on available data). There was no significant association between the underlying genotype and lumasiran response, albeit with a trend towards a lesser response in vitamin B6- sensitive forms. The only significant determinants found to be associated with the primary outcome were age at diagnosis and age at lumasiran initiation, the best response being observed in pediatric patients. CONCLUSIONS: Our study suggests a better response to lumasiran in children independent of the underlying genotype. In patients with pyridoxine sensitivity, we suggest continuing or initiating pyridoxine even after lumasiran initiation. After lumasiran initiation, a close follow-up and re-evaluation should be systematically performed.
引用
- Soncin V, Sellier Leclerc AL, Acquaviva-Bourdain C, et al. Data from the French Daily-Luma cohort suggest predictors of a lumasiran response. Kidney Int. 2026. PMID: 42805337. doi:10.1016/j.kint.2026.08.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。